Bylsma L, Fryzek J, Movva N, Frankenfeld C, Hooda N, Pundole X, et al. 2022. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. PROSPERO 2022 CRD42022351119
Abstract
Review questions
• In the published literature, what is the reported prevalence of DLL3 expression and positivity in the SCLC population?
• In the published literature, what is the prognostic impact of level of DLL3 expression and/or positivity on small-cell lung cancer (SCLC) patient survival (overall survival [OS], progression-free survival [PFS]) and treatment response (overall response rate [ORR], progressive disease [PD])?
• In the published literature, what is the reported prevalence of DLL3 expression and positivity in the SCLC population stratified by demographic or clinical factors such as age, sex, race/ethnicity, smoking status, DLL3 testing method, and % of tumor cell positivity and/or staining intensity and/or H-score?
• In the published literature, what is the effect of clinical and demographic factors such as age, sex, race/ethnicity, smoking status, DLL3 testing method, and % of tumor cell positivity and/or staining intensity and/or H-score on the prognostic value of DLL3 expression in SCLC?